HANDBOOK OF GENERAL MEDICINE VOL 1:@0.076190:0.972666:0.349932:0.972666:0.349932:0.958637:0.076190:0.958637:0.009179:0.009945:0.009945:0.009999:0.007714:0.011679:0.011679:0.007943:0.003723:0.011679:0.006518:0.003723:0.011719:0.007203:0.009945:0.007203:0.008158:0.009945:0.006209:0.003723:0.012351:0.007203:0.009999:0.003037:0.010926:0.003037:0.009945:0.007203:0.003723:0.009434:0.011679:0.006209:0.003723:0.007445
12:@0.083944:0.033217:0.104640:0.033217:0.104640:0.013052:0.083944:0.013052:0.010348:0.010348
TREATMENT AppROACHEs:@0.397030:0.032906:0.624375:0.032906:0.624375:0.013617:0.397030:0.013617:0.007872:0.011217:0.009905:0.013674:0.007872:0.016982:0.009905:0.013674:0.007872:0.005119:0.013674:0.010939:0.010939:0.011217:0.016058:0.013674:0.015023:0.012621:0.009905:0.009202
HeArt fAilure AnD DiAbetes:@0.076182:0.087643:0.333408:0.087643:0.333408:0.067479:0.076182:0.067479:0.012566:0.009609:0.013674:0.010718:0.007761:0.005174:0.008870:0.013674:0.005174:0.008131:0.011826:0.010718:0.009609:0.005174:0.013674:0.013674:0.012935:0.005174:0.012935:0.005174:0.013674:0.010718:0.009609:0.007761:0.009609:0.009609
Heart  failure  has a  bilateral interaction  with  diabetes. :@0.076190:0.103581:0.485115:0.103581:0.485115:0.087798:0.076190:0.087798:0.010326:0.009827:0.010326:0.004551:0.005125:0.004188:0.002480:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.002480:0.009223:0.010326:0.005866:0.006683:0.010326:0.004188:0.002480:0.010311:0.003024:0.003024:0.010326:0.005125:0.009827:0.004551:0.010326:0.003024:0.006683:0.003024:0.009223:0.005125:0.009827:0.004551:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.002464:0.012564:0.003024:0.005125:0.009223:0.004188:0.002480:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188:0.004188
Therefore, diabetic patients have a higher risk of devel-:@0.076190:0.117735:0.480942:0.117735:0.480942:0.101953:0.076190:0.101953:0.006441:0.009223:0.009827:0.004551:0.009827:0.004747:0.009903:0.004551:0.009827:0.004188:0.004339:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.004369:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004354:0.009223:0.010326:0.008376:0.009827:0.004369:0.010326:0.004354:0.009223:0.003024:0.010175:0.009223:0.009827:0.004551:0.004354:0.004551:0.003024:0.005866:0.007590:0.004354:0.009903:0.004747:0.004354:0.010357:0.009827:0.008376:0.009827:0.003024:0.005020
oping cardiac failure, and heart-failure patients have a :@0.076190:0.131890:0.485145:0.131890:0.485145:0.116108:0.076190:0.116108:0.009903:0.010311:0.003024:0.009223:0.010175:0.004218:0.009782:0.010326:0.004551:0.010357:0.003024:0.010326:0.009782:0.004218:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.004218:0.010326:0.009223:0.010357:0.004218:0.009223:0.009827:0.010326:0.004551:0.005125:0.005020:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004218:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004218:0.009223:0.010326:0.008376:0.009827:0.004218:0.010326:0.004188
higher risk of developing diabetes. Only metformin and :@0.076190:0.146045:0.485130:0.146045:0.485130:0.130262:0.076190:0.130262:0.009223:0.003024:0.010175:0.009223:0.009827:0.004551:0.004566:0.004551:0.003024:0.005866:0.007590:0.004581:0.009903:0.004747:0.004566:0.010357:0.009827:0.008376:0.009827:0.003024:0.009903:0.010311:0.003024:0.009223:0.010175:0.004566:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188:0.004566:0.013138:0.009223:0.003024:0.008104:0.004581:0.014182:0.009827:0.005125:0.004747:0.009903:0.004551:0.014182:0.003024:0.009223:0.004566:0.010326:0.009223:0.010357:0.004188
the  sGLT2 inhibitors act independently of insulin, and :@0.076190:0.160200:0.485145:0.160200:0.485145:0.144417:0.076190:0.144417:0.005125:0.009223:0.009827:0.004188:0.003069:0.007529:0.013184:0.006985:0.006441:0.008376:0.007257:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.007257:0.010326:0.009782:0.005125:0.007257:0.003024:0.009223:0.010357:0.009827:0.010311:0.009827:0.009223:0.010357:0.009827:0.009223:0.005125:0.003024:0.008104:0.007257:0.009903:0.004747:0.007257:0.003024:0.009223:0.005866:0.009192:0.003024:0.003024:0.009223:0.004188:0.007257:0.010326:0.009223:0.010357:0.004188
therefore have unique benefits in the management of :@0.076190:0.174354:0.485160:0.174354:0.485160:0.158572:0.076190:0.158572:0.005125:0.009223:0.009827:0.004551:0.009827:0.004747:0.009903:0.004551:0.009827:0.005367:0.009223:0.010326:0.008376:0.009827:0.005382:0.009192:0.009223:0.003024:0.010311:0.009192:0.009827:0.005382:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.005866:0.005382:0.003024:0.009223:0.005382:0.005125:0.009223:0.009827:0.005382:0.014182:0.010326:0.009223:0.010326:0.010175:0.009827:0.014182:0.009827:0.009223:0.005125:0.005367:0.009903:0.004747:0.004188
the patient with both diabetes and heart failure. sGLT2 :@0.076190:0.188509:0.485145:0.188509:0.485145:0.172726:0.076190:0.172726:0.005125:0.009223:0.009827:0.004762:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.004762:0.012564:0.003024:0.005125:0.009223:0.004762:0.010311:0.009903:0.005125:0.009223:0.004762:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004778:0.010326:0.009223:0.010357:0.004762:0.009223:0.009827:0.010326:0.004551:0.005125:0.004762:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.004762:0.007529:0.013184:0.006985:0.006441:0.008376:0.004188
inhibitors are beneficial in patients with heart failure as :@0.076190:0.202664:0.485160:0.202664:0.485160:0.186881:0.076190:0.186881:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.005397:0.010326:0.004551:0.009827:0.005382:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.009782:0.003024:0.010326:0.003024:0.005397:0.003024:0.009223:0.005397:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005397:0.012564:0.003024:0.005125:0.009223:0.005397:0.009223:0.009827:0.010326:0.004551:0.005125:0.005382:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.005397:0.010326:0.005866:0.004188
they have a diuretic effect, and are cardio- as well as :@0.076190:0.216819:0.485130:0.216819:0.485130:0.201036:0.076190:0.201036:0.005125:0.009223:0.009827:0.008104:0.005277:0.009223:0.010326:0.008376:0.009827:0.005292:0.010326:0.005292:0.010357:0.003024:0.009192:0.004551:0.009827:0.005125:0.003024:0.009782:0.005277:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.004188:0.005277:0.010326:0.009223:0.010357:0.005292:0.010326:0.004551:0.009827:0.005292:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.005020:0.005292:0.010326:0.005866:0.005292:0.012564:0.009827:0.003024:0.003024:0.005292:0.010326:0.005866:0.004188
renal-protective. They have significant benefits in reduc:@0.076190:0.230973:0.475938:0.230973:0.475938:0.215191:0.076190:0.215191:0.004551:0.009827:0.009223:0.010326:0.003024:0.005020:0.010311:0.004551:0.009903:0.005125:0.009827:0.009782:0.005125:0.003024:0.008376:0.009827:0.004188:0.003281:0.006441:0.009223:0.009827:0.008104:0.003296:0.009223:0.010326:0.008376:0.009827:0.003296:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009782:0.010326:0.009223:0.005125:0.003296:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.005866:0.003296:0.003024:0.009223:0.003296:0.004551:0.009827:0.010357:0.009192:0.009782
-:@0.475938:0.230973:0.480957:0.230973:0.480957:0.215191:0.475938:0.215191:0.005020
ing mortality and morbidity not only in diabetic patients, :@0.076190:0.245128:0.485115:0.245128:0.485115:0.229345:0.076190:0.229345:0.003024:0.009223:0.010175:0.003613:0.014182:0.009903:0.004551:0.005125:0.010326:0.003024:0.003024:0.005125:0.008104:0.003613:0.010326:0.009223:0.010357:0.003613:0.014182:0.009903:0.004551:0.010311:0.003024:0.010357:0.003024:0.005125:0.008104:0.003613:0.009223:0.009903:0.005125:0.003613:0.009903:0.009223:0.003024:0.008104:0.003613:0.003024:0.009223:0.003613:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.003629:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188:0.004188
but also in heart-failure patients. For this reason, their in-:@0.076190:0.259283:0.480942:0.259283:0.480942:0.243500:0.076190:0.243500:0.010311:0.009192:0.005125:0.004339:0.010326:0.003024:0.005866:0.009903:0.004339:0.003024:0.009223:0.004339:0.009223:0.009827:0.010326:0.004551:0.005125:0.005020:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004339:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188:0.004339:0.007333:0.009903:0.004551:0.004339:0.005125:0.009223:0.003024:0.005866:0.004339:0.004551:0.009827:0.010326:0.005866:0.009903:0.009223:0.004188:0.004339:0.005125:0.009223:0.009827:0.003024:0.004551:0.004339:0.003024:0.009223:0.005020
clusion in the management algorithm for heart-failure :@0.076190:0.273437:0.485130:0.273437:0.485130:0.257655:0.076190:0.257655:0.009782:0.003024:0.009192:0.005866:0.003024:0.009903:0.009223:0.006410:0.003024:0.009223:0.006410:0.005125:0.009223:0.009827:0.006395:0.014182:0.010326:0.009223:0.010326:0.010175:0.009827:0.014182:0.009827:0.009223:0.005125:0.006395:0.010326:0.003024:0.010175:0.009903:0.004551:0.003024:0.005125:0.009223:0.014182:0.006395:0.004747:0.009903:0.004551:0.006395:0.009223:0.009827:0.010326:0.004551:0.005125:0.005020:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188
patients who may or may not be diabetic is under con-:@0.076190:0.287592:0.480942:0.287592:0.480942:0.271809:0.076190:0.271809:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004248:0.012564:0.009223:0.009903:0.004233:0.014182:0.010326:0.008104:0.004248:0.009903:0.004551:0.004233:0.014182:0.010326:0.008104:0.004248:0.009223:0.009903:0.005125:0.004233:0.010311:0.009827:0.004248:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.004248:0.003024:0.005866:0.004248:0.009192:0.009223:0.010357:0.009827:0.004551:0.004233:0.009782:0.009903:0.009223:0.005020
sideration.:@0.076190:0.301747:0.151604:0.301747:0.151604:0.285964:0.076190:0.285964:0.005866:0.003024:0.010357:0.009827:0.004551:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188
9,10:@0.151601:0.296516:0.168604:0.296516:0.168604:0.287362:0.151601:0.287362:0.004858:0.002429:0.004858:0.004858
The  development  of  the  ARNI  (angiotensin  recep-:@0.090476:0.315975:0.480925:0.315975:0.480925:0.300192:0.090476:0.300192:0.006441:0.009223:0.009827:0.004188:0.004369:0.010357:0.009827:0.008376:0.009827:0.003024:0.009903:0.010311:0.014182:0.009827:0.009223:0.005125:0.004188:0.004369:0.009903:0.004747:0.004188:0.004369:0.005125:0.009223:0.009827:0.004188:0.004369:0.011188:0.009177:0.011188:0.003417:0.004188:0.004369:0.005579:0.010326:0.009223:0.010175:0.003024:0.009903:0.005125:0.009827:0.009223:0.005866:0.003024:0.009223:0.004188:0.004369:0.004551:0.009827:0.009782:0.009827:0.010311:0.005020
tor blocker/neprilysin  inhibitor) group of agents was :@0.076189:0.330129:0.485128:0.330129:0.485128:0.314347:0.076189:0.314347:0.005125:0.009903:0.004551:0.009389:0.010311:0.003024:0.009903:0.009782:0.007590:0.009827:0.004551:0.006607:0.009223:0.009812:0.010311:0.004551:0.003024:0.003024:0.008104:0.005866:0.003024:0.009223:0.004188:0.005216:0.003024:0.009223:0.009223:0.003024:0.010311:0.003024:0.005125:0.009903:0.004551:0.005579:0.009389:0.010175:0.004551:0.009903:0.009192:0.010311:0.009389:0.009903:0.004747:0.009389:0.010326:0.010175:0.009827:0.009223:0.005125:0.005866:0.009389:0.012564:0.010326:0.005866:0.004188
ground-breaking. This agent has improved the outlook :@0.076189:0.344284:0.485158:0.344284:0.485158:0.328501:0.076189:0.328501:0.010175:0.004551:0.009903:0.009192:0.009223:0.010357:0.005020:0.010311:0.004551:0.009827:0.010326:0.007590:0.003024:0.009223:0.010175:0.004188:0.005518:0.006441:0.009223:0.003024:0.005866:0.005534:0.010326:0.010175:0.009827:0.009223:0.005125:0.005518:0.009223:0.010326:0.005866:0.005534:0.003024:0.014182:0.010311:0.004551:0.009903:0.008376:0.009827:0.010357:0.005534:0.005125:0.009223:0.009827:0.005518:0.009903:0.009192:0.005125:0.003024:0.009903:0.009903:0.007590:0.004188
for patients with heart failure, especially those with re-:@0.076189:0.358439:0.480940:0.358439:0.480940:0.342656:0.076189:0.342656:0.004747:0.009903:0.004551:0.005806:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005806:0.012564:0.003024:0.005125:0.009223:0.005806:0.009223:0.009827:0.010326:0.004551:0.005125:0.005806:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.005806:0.009827:0.005866:0.010311:0.009827:0.009782:0.003024:0.010326:0.003024:0.003024:0.008104:0.005821:0.005125:0.009223:0.009903:0.005866:0.009827:0.005806:0.012564:0.003024:0.005125:0.009223:0.005806:0.004551:0.009827:0.005020
duced ejection fraction (HF-rEF).:@0.076189:0.372594:0.318910:0.372594:0.318910:0.356811:0.076189:0.356811:0.010357:0.009192:0.009782:0.009827:0.010357:0.006244:0.009827:0.003069:0.009827:0.009782:0.005125:0.003024:0.009903:0.009223:0.006244:0.004747:0.004551:0.010326:0.009782:0.005125:0.003024:0.009903:0.009223:0.006244:0.005579:0.010326:0.007333:0.005020:0.004551:0.008104:0.007333:0.005579:0.004188
12,13:@0.318901:0.367314:0.340762:0.367314:0.340762:0.358160:0.318901:0.358160:0.004858:0.004858:0.002429:0.004858:0.004858
 It is equally effec-:@0.340767:0.372613:0.480951:0.372613:0.480951:0.356830:0.340767:0.356830:0.006244:0.003417:0.005125:0.006244:0.003024:0.005866:0.006244:0.009827:0.010311:0.009192:0.010326:0.003024:0.003024:0.008104:0.006259:0.009827:0.004747:0.004747:0.009827:0.009782:0.005020
tive whether patients have diabetes or not. The results of :@0.076184:0.386768:0.485109:0.386768:0.485109:0.370985:0.076184:0.370985:0.005125:0.003024:0.008376:0.009827:0.003372:0.012564:0.009223:0.009827:0.005125:0.009223:0.009827:0.004551:0.003356:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.003372:0.009223:0.010326:0.008376:0.009827:0.003372:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.003372:0.009903:0.004551:0.003372:0.009223:0.009903:0.005125:0.004188:0.003356:0.006441:0.009223:0.009827:0.003372:0.004551:0.009827:0.005866:0.009192:0.003024:0.005125:0.005866:0.003372:0.009903:0.004747:0.004188
the pARADIGM study prompted the adjustment of the :@0.076184:0.400922:0.485124:0.400922:0.485124:0.385140:0.076184:0.385140:0.005125:0.009223:0.009827:0.005685:0.008950:0.011188:0.009162:0.011188:0.011249:0.003417:0.013184:0.013894:0.005700:0.005866:0.005125:0.009192:0.010357:0.008104:0.005700:0.010311:0.004551:0.009903:0.014182:0.010311:0.005125:0.009827:0.010357:0.005685:0.005125:0.009223:0.009827:0.005685:0.010326:0.010357:0.003069:0.009192:0.005866:0.005125:0.014182:0.009827:0.009223:0.005125:0.005700:0.009903:0.004747:0.005685:0.005125:0.009223:0.009827:0.004188
European and other international guidelines for heart-:@0.076184:0.415077:0.480936:0.415077:0.480936:0.399295:0.076184:0.399295:0.008104:0.009192:0.004551:0.009903:0.010311:0.009827:0.010326:0.009223:0.006002:0.010326:0.009223:0.010357:0.006017:0.009903:0.005125:0.009223:0.009827:0.004551:0.006002:0.003024:0.009223:0.005125:0.009827:0.004551:0.009223:0.010326:0.005125:0.003024:0.009903:0.009223:0.010326:0.003024:0.006002:0.010175:0.009192:0.003024:0.010357:0.009827:0.003024:0.003024:0.009223:0.009827:0.005866:0.006017:0.004747:0.009903:0.004551:0.006002:0.009223:0.009827:0.010326:0.004551:0.005125:0.005020
failure treatment to include the ARNIs and valsartan/sa-:@0.076184:0.429232:0.480951:0.429232:0.480951:0.413449:0.076184:0.413449:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.003916:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.003916:0.005125:0.009903:0.003916:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.003916:0.005125:0.009223:0.009827:0.003916:0.011188:0.009177:0.011188:0.003417:0.005866:0.003916:0.010326:0.009223:0.010357:0.003916:0.008376:0.010326:0.003024:0.005866:0.010326:0.004551:0.005125:0.010326:0.009223:0.006607:0.005866:0.010341:0.005020
cubitril in the treatment algorithm for heart-failure man-:@0.076184:0.443387:0.480921:0.443387:0.480921:0.427604:0.076184:0.427604:0.009782:0.009192:0.010311:0.003024:0.005125:0.004551:0.003024:0.003024:0.004400:0.003024:0.009223:0.004400:0.005125:0.009223:0.009827:0.004385:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004385:0.010326:0.003024:0.010175:0.009903:0.004551:0.003024:0.005125:0.009223:0.014182:0.004385:0.004747:0.009903:0.004551:0.004385:0.009223:0.009827:0.010326:0.004551:0.005125:0.005020:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004385:0.014182:0.010326:0.009223:0.005020
agement.:@0.076184:0.457541:0.149058:0.457541:0.149058:0.441759:0.076184:0.441759:0.010326:0.010175:0.009827:0.014182:0.009827:0.009223:0.005125:0.004188
14:@0.149054:0.452272:0.158770:0.452272:0.158770:0.443118:0.149054:0.443118:0.004858:0.004858
  These  agents  have  the  combined  benefit :@0.158774:0.457571:0.485148:0.457571:0.485148:0.441788:0.158774:0.441788:0.004188:0.002525:0.006441:0.009223:0.009827:0.005866:0.009827:0.004188:0.002510:0.010326:0.010175:0.009827:0.009223:0.005125:0.005866:0.004188:0.002525:0.009223:0.010326:0.008376:0.009827:0.004188:0.002525:0.005125:0.009223:0.009827:0.004188:0.002510:0.009782:0.009903:0.014182:0.010311:0.003024:0.009223:0.009827:0.010357:0.004188:0.002525:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.004188
of RAAs blockade and vasoconstriction, in addition to :@0.076194:0.471725:0.485133:0.471725:0.485133:0.455943:0.076194:0.455943:0.009903:0.004747:0.005458:0.009177:0.011188:0.011188:0.007529:0.005458:0.010311:0.003024:0.009903:0.009782:0.007590:0.010326:0.010357:0.009827:0.005458:0.010326:0.009223:0.010357:0.005458:0.008376:0.010326:0.005866:0.009903:0.009782:0.009903:0.009223:0.005866:0.005125:0.004551:0.003024:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.005443:0.003024:0.009223:0.005458:0.010326:0.010357:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223:0.005458:0.005125:0.009903:0.004188
their vasodilatory effect on the vaso-active peptide sys-:@0.076194:0.485880:0.480930:0.485880:0.480930:0.470097:0.076194:0.470097:0.005125:0.009223:0.009827:0.003024:0.004551:0.003870:0.008376:0.010326:0.005866:0.009903:0.010357:0.003024:0.003024:0.010326:0.005125:0.009903:0.004551:0.008104:0.003886:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.003870:0.009903:0.009223:0.003870:0.005125:0.009223:0.009827:0.003886:0.008376:0.010326:0.005866:0.009903:0.005020:0.010326:0.009782:0.005125:0.003024:0.008376:0.009827:0.003886:0.010311:0.009827:0.010311:0.005125:0.003024:0.010357:0.009827:0.003886:0.005866:0.008104:0.005866:0.005020
tem, including brain natriuretic peptide (BNp). The addi-:@0.076194:0.500035:0.480945:0.500035:0.480945:0.484252:0.076194:0.484252:0.005125:0.009827:0.014182:0.004188:0.003674:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.003024:0.009223:0.010175:0.003674:0.010311:0.004551:0.010326:0.003024:0.009223:0.003674:0.009223:0.010326:0.005125:0.004551:0.003024:0.009192:0.004551:0.009827:0.005125:0.003024:0.009782:0.003659:0.010311:0.009827:0.010311:0.005125:0.003024:0.010357:0.009827:0.003674:0.005579:0.008678:0.011188:0.008950:0.005579:0.004188:0.003674:0.006441:0.009223:0.009827:0.003674:0.010326:0.010357:0.010357:0.003024:0.005020
tion of ARNIs will reduce hospitalisations for heart failure, :@0.076194:0.514189:0.485118:0.514189:0.485118:0.498407:0.076194:0.498407:0.005125:0.003024:0.009903:0.009223:0.003810:0.009903:0.004747:0.003810:0.011188:0.009177:0.011188:0.003417:0.005866:0.003810:0.012564:0.003024:0.003024:0.003024:0.003825:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.003810:0.009223:0.009903:0.005866:0.010311:0.003024:0.005125:0.010326:0.003024:0.003024:0.005866:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.003825:0.004747:0.009903:0.004551:0.003810:0.009223:0.009827:0.010326:0.004551:0.005125:0.003810:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.004188:0.004188
as well as heart failure in deterioration despite optimal :@0.076194:0.528344:0.485118:0.528344:0.485118:0.512562:0.076194:0.512562:0.010326:0.005866:0.005367:0.012564:0.009827:0.003024:0.003024:0.005367:0.010326:0.005866:0.005367:0.009223:0.009827:0.010326:0.004551:0.005125:0.005367:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.005367:0.003024:0.009223:0.005367:0.010357:0.009827:0.005125:0.009827:0.004551:0.003024:0.009903:0.004551:0.010326:0.005125:0.003024:0.009903:0.009223:0.005352:0.010357:0.009827:0.005866:0.010311:0.003024:0.005125:0.009827:0.005367:0.009903:0.010311:0.005125:0.003024:0.014182:0.010326:0.003024:0.004188
medical therapy.:@0.076194:0.542499:0.202558:0.542499:0.202558:0.526716:0.076194:0.526716:0.014182:0.009827:0.010357:0.003024:0.009782:0.010326:0.003024:0.004188:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188
liPiD COntrOl:@0.076190:0.575435:0.208868:0.575435:0.208868:0.555270:0.076190:0.555270:0.008131:0.005174:0.010348:0.005174:0.012935:0.005174:0.014413:0.015522:0.013674:0.007761:0.010718:0.015522:0.008131
The lipid guidelines have also been updated, and in the :@0.076190:0.591373:0.485115:0.591373:0.485115:0.575590:0.076190:0.575590:0.006441:0.009223:0.009827:0.003765:0.003024:0.003024:0.010311:0.003024:0.010372:0.003765:0.010175:0.009192:0.003024:0.010357:0.009827:0.003024:0.003024:0.009223:0.009827:0.005866:0.003765:0.009223:0.010326:0.008376:0.009827:0.003765:0.010326:0.003024:0.005866:0.009903:0.003765:0.010311:0.009827:0.009827:0.009223:0.003765:0.009192:0.010311:0.010357:0.010326:0.005125:0.009827:0.010357:0.004188:0.003765:0.010326:0.009223:0.010357:0.003765:0.003024:0.009223:0.003765:0.005125:0.009223:0.009827:0.004188
setting of cardiovascular disease  remain a critical as-:@0.076190:0.605527:0.480942:0.605527:0.480942:0.589745:0.076190:0.589745:0.005866:0.009827:0.005125:0.005125:0.003024:0.009223:0.010175:0.006562:0.009903:0.004747:0.006562:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.006562:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004188:0.002389:0.004551:0.009827:0.014182:0.010326:0.003024:0.009223:0.006562:0.010326:0.006562:0.009782:0.004551:0.003024:0.005125:0.003024:0.009782:0.010326:0.003024:0.006562:0.010326:0.005866:0.005020
pect of treatment. The south African guidelines include :@0.076190:0.619682:0.485130:0.619682:0.485130:0.603900:0.076190:0.603900:0.010311:0.009827:0.009782:0.005125:0.004324:0.009903:0.004747:0.004339:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009812:0.009223:0.005125:0.004188:0.004324:0.006441:0.009223:0.009827:0.004324:0.007529:0.009903:0.009192:0.005125:0.009223:0.004324:0.011188:0.004747:0.004551:0.003024:0.009782:0.010326:0.009223:0.004324:0.010175:0.009192:0.003024:0.010357:0.009827:0.003024:0.003024:0.009223:0.009827:0.005866:0.004339:0.003024:0.009223:0.009782:0.003024:0.009192:0.010357:0.009827:0.004188
an extensive assessment of the age and risk profile, as :@0.076190:0.633837:0.485130:0.633837:0.485130:0.618054:0.076190:0.618054:0.010326:0.009223:0.005488:0.009827:0.007257:0.005125:0.009827:0.009223:0.005866:0.003024:0.008376:0.009827:0.005503:0.010326:0.005866:0.005866:0.009827:0.005866:0.005866:0.014182:0.009827:0.009223:0.005125:0.005503:0.009903:0.004747:0.005488:0.005125:0.009223:0.009827:0.005488:0.010326:0.010175:0.009827:0.005488:0.010326:0.009223:0.010357:0.005488:0.004551:0.003024:0.005866:0.007590:0.005488:0.010311:0.004551:0.009903:0.003681:0.003681:0.003024:0.009827:0.004188:0.005488:0.010326:0.005866:0.004188
well as existing risk factors for accelerated atheroscle-:@0.076190:0.647992:0.480957:0.647992:0.480957:0.632209:0.076190:0.632209:0.012564:0.009827:0.003024:0.003024:0.005836:0.010326:0.005866:0.005836:0.009827:0.007257:0.003024:0.005866:0.005125:0.003024:0.009223:0.010175:0.005836:0.004551:0.003024:0.005866:0.007590:0.005836:0.004747:0.010326:0.009782:0.005125:0.009903:0.004551:0.005866:0.005836:0.004747:0.009903:0.004551:0.005836:0.010326:0.009782:0.009782:0.009827:0.003024:0.009827:0.004551:0.010326:0.005125:0.009827:0.010357:0.005836:0.010326:0.005125:0.009223:0.009827:0.004551:0.009903:0.005866:0.009782:0.003024:0.009827:0.005020
rosis. In this guideline, diabetes and renal  impairment :@0.076190:0.662146:0.485160:0.662146:0.485160:0.646364:0.076190:0.646364:0.004551:0.009903:0.005866:0.003024:0.005866:0.004188:0.006909:0.003417:0.009223:0.006909:0.005125:0.009223:0.003024:0.005866:0.006909:0.010175:0.009192:0.003024:0.010357:0.009827:0.003024:0.003024:0.009223:0.009827:0.004188:0.006909:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.006909:0.010326:0.009223:0.010357:0.006909:0.004551:0.009827:0.009223:0.010326:0.003024:0.004188:0.002706:0.003024:0.014182:0.010311:0.010326:0.003024:0.004551:0.014182:0.009827:0.009223:0.005125:0.004188
are  considered compelling reasons  for  the  manage-:@0.076190:0.676301:0.480942:0.676301:0.480942:0.660518:0.076190:0.660518:0.010326:0.004551:0.009827:0.004188:0.003613:0.009782:0.009903:0.009223:0.005866:0.003024:0.010357:0.009827:0.004551:0.009827:0.010357:0.007817:0.009782:0.009903:0.014182:0.010311:0.009827:0.003024:0.003024:0.003024:0.009223:0.010175:0.007817:0.004551:0.009827:0.010326:0.005866:0.009903:0.009223:0.005866:0.004188:0.003613:0.004747:0.009903:0.004551:0.004188:0.003613:0.005125:0.009223:0.009827:0.004188:0.003613:0.014182:0.010326:0.009223:0.010326:0.010175:0.009827:0.005020
ment of dyslipidaemia with high-intensity statins, rosuv-:@0.076190:0.690456:0.480957:0.690456:0.480957:0.674673:0.076190:0.674673:0.014182:0.009827:0.009223:0.005125:0.005534:0.009903:0.004747:0.005534:0.010357:0.008104:0.005866:0.003024:0.003024:0.010311:0.003039:0.010357:0.010326:0.009827:0.014182:0.003024:0.010326:0.005534:0.012564:0.003024:0.005125:0.009223:0.005534:0.009223:0.003024:0.010175:0.009223:0.005020:0.003024:0.009223:0.005125:0.009827:0.009223:0.005866:0.003024:0.005125:0.008104:0.005534:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.004188:0.005534:0.004551:0.009903:0.005866:0.009192:0.008376:0.005020
astatin and atorvastatin. If the LDLc is not at the target :@0.076190:0.704610:0.485145:0.704610:0.485145:0.688828:0.076190:0.688828:0.010326:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004914:0.010326:0.009223:0.010357:0.004914:0.010326:0.005125:0.009903:0.004551:0.008376:0.010326:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004188:0.004914:0.003417:0.004747:0.004914:0.005125:0.009223:0.009827:0.004914:0.006985:0.011249:0.006985:0.009782:0.004914:0.003024:0.005866:0.004914:0.009223:0.009903:0.005125:0.004899:0.010326:0.005125:0.004914:0.005125:0.009223:0.009827:0.004914:0.005125:0.010326:0.004551:0.010175:0.009827:0.005125:0.004188
level of <1,8 mmol/L despite maximum statin dosages, :@0.076190:0.718765:0.485130:0.718765:0.485130:0.702983:0.076190:0.702983:0.003024:0.009827:0.008376:0.009827:0.003024:0.005594:0.009903:0.004747:0.005594:0.009162:0.008376:0.004188:0.008376:0.005594:0.014182:0.014182:0.009903:0.003024:0.006607:0.006985:0.005594:0.010357:0.009827:0.005866:0.010311:0.003024:0.005125:0.009827:0.005594:0.014182:0.010326:0.007257:0.003024:0.014182:0.009192:0.014182:0.005594:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005594:0.010357:0.009903:0.005866:0.010326:0.010175:0.009827:0.005866:0.004188:0.004188
ezetimibe should be added to achieve the target levels. :@0.076190:0.732920:0.485115:0.732920:0.485115:0.717137:0.076190:0.717137:0.009827:0.006426:0.009827:0.005125:0.003024:0.014182:0.003024:0.010311:0.009827:0.003175:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.003175:0.010311:0.009827:0.003175:0.010326:0.010357:0.010357:0.009827:0.010357:0.003175:0.005125:0.009903:0.003175:0.010326:0.009782:0.009223:0.003024:0.009827:0.008376:0.009827:0.003175:0.005125:0.009223:0.009827:0.003175:0.005125:0.010326:0.004551:0.010175:0.009827:0.005125:0.003160:0.003024:0.009827:0.008376:0.009827:0.003024:0.005866:0.004188:0.004188
The newer therapies that are available, e.g. pCsK9 inhi-:@0.076190:0.747075:0.480957:0.747075:0.480957:0.731292:0.076190:0.731292:0.006441:0.009223:0.009827:0.004233:0.009223:0.009827:0.012564:0.009827:0.004551:0.004233:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.003024:0.009827:0.005866:0.004248:0.005125:0.009223:0.010326:0.005125:0.004248:0.010326:0.004551:0.009827:0.004248:0.010326:0.008376:0.010326:0.003024:0.003024:0.010326:0.010311:0.003024:0.009827:0.004188:0.004264:0.009827:0.004188:0.010175:0.004188:0.004248:0.008950:0.012292:0.007529:0.008935:0.008376:0.004248:0.003024:0.009223:0.009223:0.003024:0.005020
bitors, have proved extremely effective in lipid reduc-:@0.076190:0.761229:0.480942:0.761229:0.480942:0.745447:0.076190:0.745447:0.010311:0.003024:0.005125:0.009903:0.004551:0.005866:0.004188:0.006138:0.009223:0.010326:0.008376:0.009827:0.006138:0.010311:0.004551:0.009903:0.008376:0.009827:0.010357:0.006138:0.009827:0.007257:0.005125:0.004551:0.009827:0.014182:0.009827:0.003024:0.008104:0.006138:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.003024:0.008376:0.009827:0.006138:0.003024:0.009223:0.006138:0.003024:0.003024:0.010311:0.003024:0.010357:0.006153:0.004551:0.009827:0.010357:0.009192:0.009782:0.005020
tion specifically to block the LDL receptor, with the result :@0.076190:0.775384:0.485130:0.775384:0.485130:0.759601:0.076190:0.759601:0.005125:0.003024:0.009903:0.009223:0.003583:0.005866:0.010311:0.009827:0.009782:0.003024:0.003681:0.003681:0.009782:0.010326:0.003024:0.003024:0.008104:0.003598:0.005125:0.009903:0.003583:0.010311:0.003024:0.009903:0.009782:0.007590:0.003583:0.005125:0.009223:0.009827:0.003583:0.006985:0.011249:0.006985:0.003583:0.004551:0.009827:0.009782:0.009827:0.010311:0.005125:0.009903:0.004551:0.004188:0.003568:0.012564:0.003024:0.005125:0.009223:0.003583:0.005125:0.009223:0.009827:0.003583:0.004551:0.009827:0.005866:0.009192:0.003024:0.005125:0.004188
that cardiovascular risk is significantly reduced.:@0.076190:0.789539:0.424503:0.789539:0.424503:0.773756:0.076190:0.773756:0.005125:0.009223:0.010326:0.005125:0.005367:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.005367:0.004551:0.003024:0.005866:0.007590:0.005367:0.003024:0.005866:0.005382:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009782:0.010326:0.009223:0.005125:0.003024:0.008104:0.005382:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.010357:0.004188
16,17,18:@0.424510:0.784308:0.458517:0.784308:0.458517:0.775154:0.424510:0.775154:0.004858:0.004858:0.002429:0.004858:0.004858:0.002429:0.004858:0.004858
 As :@0.458525:0.789607:0.485134:0.789607:0.485134:0.773824:0.458525:0.773824:0.005367:0.011188:0.005866:0.004188
the costs are high, there will be specific cases and indi:@0.076194:0.803762:0.475912:0.803762:0.475912:0.787979:0.076194:0.787979:0.005125:0.009223:0.009827:0.004490:0.009782:0.009903:0.005866:0.005125:0.005866:0.004505:0.010326:0.004551:0.009827:0.004490:0.009223:0.003024:0.010175:0.009223:0.004188:0.004490:0.005125:0.009223:0.009827:0.004551:0.009827:0.004490:0.012564:0.003024:0.003024:0.003024:0.004505:0.010311:0.009827:0.004490:0.005866:0.010311:0.009827:0.009782:0.003024:0.003681:0.003681:0.009782:0.004505:0.009782:0.010326:0.005866:0.009827:0.005866:0.004505:0.010326:0.009223:0.010357:0.004505:0.003024:0.009223:0.010357:0.003024
-:@0.475912:0.803762:0.480931:0.803762:0.480931:0.787979:0.475912:0.787979:0.005020
cations for their use, but their benefit has been demon:@0.076194:0.817916:0.475912:0.817916:0.475912:0.802134:0.076194:0.802134:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.005866:0.004475:0.004747:0.009903:0.004551:0.004475:0.005125:0.009223:0.009827:0.003024:0.004551:0.004475:0.009192:0.005866:0.009827:0.004188:0.004475:0.010311:0.009192:0.005125:0.004475:0.005125:0.009223:0.009827:0.003024:0.004551:0.004475:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.004475:0.009223:0.010326:0.005866:0.004490:0.010311:0.009827:0.009827:0.009223:0.004475:0.010357:0.009827:0.014182:0.009903:0.009223
-:@0.475912:0.817916:0.480931:0.817916:0.480931:0.802134:0.475912:0.802134:0.005020
strated using two different agents and in two individual :@0.076194:0.832071:0.485134:0.832071:0.485134:0.816289:0.076194:0.816289:0.005866:0.005125:0.004551:0.010326:0.005125:0.009827:0.010357:0.004611:0.009192:0.005866:0.003024:0.009223:0.010175:0.004611:0.005125:0.012564:0.009903:0.004596:0.010357:0.003024:0.004747:0.004747:0.009827:0.004551:0.009827:0.009223:0.005125:0.004596:0.010326:0.010175:0.009827:0.009223:0.005125:0.005866:0.004611:0.010326:0.009223:0.010357:0.004611:0.003024:0.009223:0.004611:0.005125:0.012564:0.009903:0.004611:0.003024:0.009223:0.010357:0.003024:0.008376:0.003024:0.010357:0.009192:0.010326:0.003024:0.004188
trials,  both  with  significant  CV  MACE  reduction.  The :@0.076194:0.846226:0.485149:0.846226:0.485149:0.830443:0.076194:0.830443:0.005125:0.004551:0.003024:0.010326:0.003024:0.005866:0.004188:0.004188:0.004672:0.010311:0.009903:0.005125:0.009223:0.004188:0.004657:0.012564:0.003024:0.005125:0.009223:0.004188:0.004672:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009782:0.010326:0.009223:0.005125:0.004188:0.004672:0.012292:0.010614:0.004188:0.004672:0.013894:0.011188:0.012292:0.008104:0.004188:0.004672:0.004551:0.009827:0.010357:0.009192:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.004188:0.004657:0.006441:0.009223:0.009827:0.004188
high-intensity statins have to be used in the manage-:@0.076194:0.860381:0.480961:0.860381:0.480961:0.844598:0.076194:0.844598:0.009223:0.003024:0.010175:0.009223:0.005020:0.003024:0.009223:0.005125:0.009827:0.009223:0.005866:0.003024:0.005125:0.008104:0.006410:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.005866:0.006426:0.009223:0.010326:0.008376:0.009827:0.006426:0.005125:0.009903:0.006410:0.010311:0.009827:0.006410:0.009192:0.005866:0.009827:0.010357:0.006426:0.003024:0.009223:0.006426:0.005125:0.009223:0.009827:0.006410:0.014182:0.010326:0.009223:0.010326:0.010175:0.009827:0.005020
ment of dyslipidaemia in the patient with diabetes. :@0.076194:0.874535:0.452628:0.874535:0.452628:0.858753:0.076194:0.858753:0.014182:0.009827:0.009223:0.005125:0.004188:0.009903:0.004747:0.004188:0.010357:0.008104:0.005866:0.003024:0.003024:0.010311:0.003024:0.010357:0.010326:0.009827:0.014182:0.003024:0.010326:0.004188:0.003024:0.009223:0.004188:0.005125:0.009223:0.009827:0.004188:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.004188:0.012564:0.003024:0.005125:0.009223:0.004188:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188:0.004188
There  remain  questions  regarding  the  addition  of  fi:@0.090482:0.888690:0.475927:0.888690:0.475927:0.872907:0.090482:0.872907:0.006441:0.009223:0.009827:0.004551:0.009827:0.004188:0.002434:0.004551:0.009827:0.014182:0.010326:0.003024:0.009223:0.004188:0.002434:0.010311:0.009192:0.009827:0.005866:0.005125:0.003024:0.009903:0.009223:0.005866:0.004188:0.002449:0.004551:0.009827:0.010175:0.010326:0.004536:0.010357:0.003024:0.009223:0.010175:0.004188:0.002434:0.005125:0.009223:0.009827:0.004188:0.002434:0.010326:0.010357:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223:0.004188:0.002449:0.009903:0.004747:0.004188:0.002434:0.003681:0.003681
-:@0.475927:0.888690:0.480946:0.888690:0.480946:0.872907:0.475927:0.872907:0.005020
brates to control HDLc and TG. The FIELD study showed :@0.076194:0.902845:0.485149:0.902845:0.485149:0.887062:0.076194:0.887062:0.010311:0.004551:0.010326:0.005125:0.009827:0.005866:0.004581:0.005125:0.009903:0.004581:0.009782:0.009903:0.009223:0.005125:0.004536:0.009903:0.003024:0.004581:0.010326:0.011249:0.006985:0.009782:0.004581:0.010326:0.009223:0.010357:0.004581:0.006441:0.013184:0.004188:0.004581:0.006441:0.009223:0.009827:0.004566:0.007333:0.003417:0.008104:0.006985:0.011249:0.004581:0.005866:0.005125:0.009192:0.010357:0.008104:0.004581:0.005866:0.009223:0.009903:0.012564:0.009827:0.010357:0.004188
benefit in reducing diabetic retinopathy – and this in the :@0.076194:0.917000:0.485119:0.917000:0.485119:0.901217:0.076194:0.901217:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.003447:0.003024:0.009223:0.003447:0.004551:0.009827:0.010357:0.009192:0.009782:0.003024:0.009223:0.010175:0.003447:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.003462:0.004551:0.009827:0.005125:0.003024:0.009223:0.009903:0.010311:0.010326:0.005125:0.009223:0.008104:0.003447:0.007560:0.003447:0.010326:0.009223:0.010357:0.003447:0.005125:0.009223:0.003024:0.005866:0.003447:0.003024:0.009223:0.003447:0.005125:0.009223:0.009827:0.004188
setting of existing early retinopathy. The use of a micro-:@0.076194:0.931154:0.480946:0.931154:0.480946:0.915372:0.076194:0.915372:0.005866:0.009827:0.005125:0.005125:0.003024:0.009223:0.010175:0.004626:0.009903:0.004747:0.004626:0.009827:0.007257:0.003024:0.005866:0.005125:0.003024:0.009223:0.010175:0.004626:0.009827:0.010326:0.004551:0.003024:0.008104:0.004626:0.004551:0.009827:0.005125:0.003024:0.009223:0.009903:0.010311:0.010326:0.005125:0.009223:0.008104:0.004188:0.004626:0.006441:0.009223:0.009827:0.004626:0.009192:0.005866:0.009827:0.004626:0.009903:0.004747:0.004626:0.010326:0.004626:0.014182:0.003024:0.009782:0.004551:0.009903:0.005020
nised fenofibrate has the most data and can be added :@0.076194:0.945309:0.485134:0.945309:0.485134:0.929526:0.076194:0.929526:0.009223:0.003024:0.005866:0.009827:0.010357:0.003765:0.004747:0.009827:0.009223:0.009903:0.003681:0.003681:0.010311:0.004551:0.010326:0.005125:0.009827:0.003750:0.009223:0.010326:0.005866:0.003765:0.005125:0.009223:0.009827:0.003750:0.014182:0.009903:0.005866:0.005125:0.003765:0.010357:0.010326:0.005125:0.010326:0.003765:0.010326:0.009223:0.010357:0.003765:0.009782:0.010326:0.009223:0.003765:0.010311:0.009827:0.003765:0.010326:0.010357:0.010357:0.009827:0.010357:0.004188
to statin therapy should the HDLc targets (>1 mmol/L in :@0.519046:0.084873:0.928001:0.084873:0.928001:0.069090:0.519046:0.069090:0.005125:0.009903:0.004687:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004702:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004702:0.005866:0.009223:0.009903:0.009192:0.003024:0.010357:0.004702:0.005125:0.009223:0.009827:0.004687:0.010326:0.011249:0.006985:0.009782:0.004702:0.005125:0.010326:0.004551:0.010175:0.009827:0.005125:0.005866:0.004687:0.005579:0.009162:0.008376:0.004702:0.014182:0.014182:0.009903:0.003024:0.006607:0.006985:0.004687:0.003024:0.009223:0.004188
men, >1,2 mmol/L in women) and TG (<1,7 mmol/L) not :@0.519046:0.099108:0.928001:0.099108:0.928001:0.083326:0.519046:0.083326:0.014182:0.009827:0.009223:0.004188:0.004324:0.009162:0.008376:0.004188:0.008376:0.004324:0.014182:0.014182:0.009903:0.003024:0.006607:0.006985:0.004324:0.003024:0.009223:0.004324:0.012564:0.009903:0.014182:0.009827:0.009223:0.005579:0.004324:0.010326:0.009223:0.010357:0.004324:0.006441:0.013184:0.004324:0.005579:0.009162:0.008376:0.004188:0.008376:0.004324:0.014182:0.014182:0.009903:0.003024:0.006607:0.006985:0.005579:0.004324:0.009223:0.009903:0.005125:0.004188
be reached. The effect on cardiovascular outcomes :@0.519046:0.113344:0.928016:0.113344:0.928016:0.097561:0.519046:0.097561:0.010311:0.009827:0.007454:0.004551:0.009827:0.010326:0.009782:0.009223:0.009827:0.010357:0.004188:0.007454:0.006441:0.009223:0.009827:0.007454:0.009827:0.004747:0.004747:0.009827:0.009782:0.005125:0.007454:0.009903:0.009223:0.007454:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.007454:0.009903:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.005866:0.004188
was disappointing in the FIELD study, but the trial design :@0.519046:0.127580:0.927986:0.127580:0.927986:0.111797:0.519046:0.111797:0.012564:0.010326:0.005866:0.004052:0.010357:0.003024:0.005866:0.010326:0.010311:0.010311:0.009903:0.003024:0.009223:0.005125:0.003024:0.009223:0.010175:0.004052:0.003024:0.009223:0.004052:0.005125:0.009223:0.009827:0.004037:0.007333:0.003417:0.008104:0.006985:0.011249:0.004052:0.005866:0.005125:0.009192:0.010357:0.008104:0.004188:0.004052:0.010311:0.009192:0.005125:0.004052:0.005125:0.009223:0.009827:0.004037:0.005125:0.004551:0.003024:0.010326:0.003024:0.004052:0.010357:0.009827:0.005866:0.003024:0.010175:0.009223:0.004188
could have been responsible, as patients in both arms :@0.519046:0.141815:0.927986:0.141815:0.927986:0.126032:0.519046:0.126032:0.009782:0.009903:0.009192:0.003024:0.010357:0.005352:0.009223:0.010326:0.008376:0.009827:0.005367:0.010311:0.009827:0.009827:0.009223:0.005352:0.004551:0.009827:0.005866:0.010311:0.009903:0.009223:0.005866:0.003024:0.010311:0.003024:0.009827:0.004188:0.005352:0.010326:0.005866:0.005367:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.005367:0.003024:0.009223:0.005367:0.010311:0.009903:0.005125:0.009223:0.005352:0.010326:0.004551:0.014182:0.005866:0.004188
received  aggressive statin  therapy  which  may have :@0.519046:0.156051:0.927986:0.156051:0.927986:0.140268:0.519046:0.140268:0.004551:0.009827:0.009782:0.009827:0.003024:0.008376:0.009827:0.010357:0.004188:0.004279:0.010326:0.010175:0.010175:0.004551:0.009827:0.005866:0.005866:0.003024:0.008376:0.009827:0.008482:0.005866:0.005125:0.010326:0.005125:0.003024:0.009223:0.004188:0.004279:0.005125:0.009223:0.009827:0.004551:0.010326:0.010311:0.008104:0.004188:0.004279:0.012564:0.009223:0.003024:0.009782:0.009223:0.004188:0.004279:0.014182:0.010326:0.008104:0.008482:0.009223:0.010326:0.008376:0.009827:0.004188
affected  the  lack  of  significant  differences  in  MACE :@0.519046:0.170286:0.927971:0.170286:0.927971:0.154503:0.519046:0.154503:0.010326:0.004747:0.004747:0.009827:0.009782:0.005125:0.009827:0.010357:0.004188:0.004067:0.005125:0.009223:0.009827:0.004188:0.004067:0.003024:0.010326:0.009782:0.007590:0.004188:0.004082:0.009903:0.004747:0.004188:0.004067:0.005866:0.003024:0.010175:0.009223:0.003024:0.003681:0.003681:0.009782:0.010326:0.009223:0.005125:0.004188:0.004067:0.010357:0.003024:0.004747:0.004747:0.009827:0.004551:0.009827:0.009223:0.009782:0.009827:0.005866:0.004188:0.004067:0.003024:0.009223:0.004188:0.004082:0.013894:0.011188:0.012292:0.008104:0.004188
outcomes  between  the  two  arms.  The  ACCORD  trial :@0.519046:0.184522:0.927971:0.184522:0.927971:0.168739:0.519046:0.168739:0.009903:0.009192:0.005125:0.009782:0.009903:0.014182:0.009827:0.005866:0.004188:0.003311:0.010311:0.009827:0.005125:0.012564:0.009827:0.009827:0.009223:0.004188:0.003311:0.005125:0.009223:0.009827:0.004188:0.003311:0.005125:0.012564:0.009903:0.004188:0.003311:0.010326:0.004551:0.014182:0.005866:0.004188:0.004188:0.003311:0.006441:0.009223:0.009827:0.004188:0.003311:0.011188:0.012292:0.012292:0.013138:0.009177:0.011249:0.004188:0.003311:0.005125:0.004551:0.003024:0.010326:0.003024:0.004188
showed a similar benefit in diabetic retinopathy, using :@0.519046:0.198757:0.928001:0.198757:0.928001:0.182975:0.519046:0.182975:0.005866:0.009223:0.009903:0.012564:0.009827:0.010357:0.005791:0.010326:0.005806:0.005866:0.003024:0.014182:0.003024:0.003039:0.010326:0.004551:0.005791:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.005791:0.003024:0.009223:0.005806:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.003024:0.009782:0.005806:0.004551:0.009827:0.005125:0.003024:0.009223:0.009903:0.010311:0.010326:0.005125:0.009223:0.008104:0.004188:0.005791:0.009192:0.005866:0.003024:0.009223:0.010175:0.004188
the micronised fenofibrate. It therefore has an addition:@0.519046:0.212993:0.918793:0.212993:0.918793:0.197210:0.519046:0.197210:0.005125:0.009223:0.009827:0.004007:0.014182:0.003024:0.009782:0.004551:0.009903:0.009223:0.003024:0.005866:0.009827:0.010357:0.004007:0.004747:0.009827:0.009223:0.009903:0.003681:0.003681:0.010311:0.004551:0.010326:0.005125:0.009827:0.004188:0.003991:0.003417:0.005125:0.004007:0.005125:0.009223:0.009827:0.004551:0.009827:0.004747:0.009903:0.004551:0.009827:0.003991:0.009223:0.010326:0.005866:0.004007:0.010326:0.009223:0.004007:0.010326:0.010357:0.010357:0.003024:0.005125:0.003024:0.009903:0.009223
-:@0.918793:0.212993:0.923813:0.212993:0.923813:0.197210:0.918793:0.197210:0.005020
al benefit beyond lipid control that must be considered :@0.519046:0.227228:0.927986:0.227228:0.927986:0.211446:0.519046:0.211446:0.010326:0.003024:0.004218:0.010311:0.009827:0.009223:0.009827:0.003681:0.003681:0.005125:0.004203:0.010311:0.009827:0.008104:0.009903:0.009223:0.010357:0.004218:0.003024:0.003024:0.010311:0.003024:0.010357:0.004233:0.009782:0.009903:0.009223:0.005125:0.004551:0.009903:0.003024:0.004203:0.005125:0.009223:0.010326:0.005125:0.004218:0.014182:0.009192:0.005866:0.005125:0.004218:0.010311:0.009827:0.004218:0.009782:0.009903:0.009223:0.005866:0.003024:0.010357:0.009827:0.004551:0.009827:0.010357:0.004188
in patients with diabetes.:@0.519046:0.241464:0.701472:0.241464:0.701472:0.225681:0.519046:0.225681:0.003024:0.009223:0.004188:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004188:0.012564:0.003024:0.005125:0.009223:0.004188:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004188
COnClusiOn:@0.519047:0.274558:0.641007:0.274558:0.641007:0.254393:0.519047:0.254393:0.014413:0.015522:0.013674:0.014413:0.008131:0.011826:0.009609:0.005174:0.015522:0.013674
The management of any patient with diabetes requires :@0.519047:0.290576:0.927987:0.290576:0.927987:0.274794:0.519047:0.274794:0.006441:0.009223:0.009827:0.004264:0.014182:0.010326:0.009223:0.010326:0.010175:0.009827:0.014182:0.009827:0.009223:0.005125:0.004248:0.009903:0.004747:0.004264:0.010326:0.009223:0.008104:0.004264:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.004264:0.012564:0.003024:0.005125:0.009223:0.004264:0.010357:0.003024:0.010326:0.010311:0.009827:0.005125:0.009827:0.005866:0.004264:0.004551:0.009827:0.010311:0.009192:0.003024:0.004551:0.009827:0.005866:0.004188
careful assessment of all the risk factors that could be :@0.519047:0.304812:0.927972:0.304812:0.927972:0.289029:0.519047:0.289029:0.009782:0.010326:0.004551:0.009827:0.004747:0.009192:0.003024:0.005836:0.010326:0.005866:0.005866:0.009827:0.005866:0.005866:0.014182:0.009827:0.009223:0.005125:0.005851:0.009903:0.004747:0.005836:0.010326:0.003024:0.003024:0.005851:0.005125:0.009223:0.009827:0.005836:0.004551:0.003024:0.005866:0.007590:0.005851:0.004747:0.010326:0.009782:0.005125:0.009903:0.004551:0.005866:0.005836:0.005125:0.009223:0.010326:0.005125:0.005836:0.009782:0.009903:0.009192:0.003024:0.010357:0.005851:0.010311:0.009827:0.004188
contributing to accelerated atherosclerosis, ischaemic :@0.519047:0.319047:0.928002:0.319047:0.928002:0.303265:0.519047:0.303265:0.009782:0.009903:0.009223:0.005125:0.004551:0.003024:0.010311:0.009192:0.005125:0.003024:0.009223:0.010175:0.005609:0.005125:0.009903:0.005609:0.010326:0.009782:0.009782:0.009827:0.003024:0.009827:0.004551:0.010326:0.005125:0.009827:0.010357:0.005609:0.010326:0.005125:0.009223:0.009827:0.004551:0.009903:0.005866:0.009782:0.003024:0.009827:0.004551:0.009903:0.005866:0.003024:0.005866:0.004188:0.005609:0.003024:0.005866:0.009782:0.009223:0.010326:0.009827:0.014182:0.003024:0.009782:0.004188
heart  disease, heart  failure and the  risk of  renal dys-:@0.519047:0.333283:0.923799:0.333283:0.923799:0.317500:0.519047:0.317500:0.009223:0.009827:0.010326:0.004551:0.005125:0.004188:0.003205:0.010357:0.003024:0.005866:0.009827:0.010326:0.005866:0.009827:0.004188:0.007408:0.009223:0.009827:0.010326:0.004551:0.005125:0.004188:0.003205:0.004747:0.010326:0.003024:0.003024:0.009192:0.004551:0.009827:0.007408:0.010326:0.009223:0.010357:0.007408:0.005125:0.009223:0.009827:0.004188:0.003205:0.004551:0.003024:0.005866:0.007590:0.007408:0.009903:0.004747:0.004188:0.003205:0.004551:0.009827:0.009223:0.010326:0.003024:0.007408:0.010357:0.008104:0.005866:0.005020
function. Newer agents are now available to manage :@0.519047:0.347518:0.928002:0.347518:0.928002:0.331736:0.519047:0.331736:0.004747:0.009192:0.009223:0.009782:0.005125:0.003024:0.009903:0.009223:0.004188:0.005397:0.011188:0.009827:0.012564:0.009827:0.004551:0.005397:0.010326:0.010175:0.009827:0.009223:0.005125:0.005866:0.005397:0.010326:0.004551:0.009827:0.005397:0.009223:0.009903:0.012564:0.005397:0.010326:0.008376:0.010326:0.003024:0.003024:0.010326:0.010311:0.003024:0.009827:0.005428:0.005125:0.009903:0.005397:0.014182:0.010326:0.009223:0.010326:0.010175:0.009827:0.004188
these patients with the best results possible.  Excellent :@0.519047:0.361754:0.928002:0.361754:0.928002:0.345971:0.519047:0.345971:0.005125:0.009223:0.009827:0.005866:0.009827:0.007121:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.007121:0.012564:0.003024:0.005125:0.009223:0.007121:0.005125:0.009223:0.009827:0.007121:0.010311:0.009827:0.005866:0.005125:0.007121:0.004551:0.009827:0.005866:0.009192:0.003024:0.005125:0.005866:0.007121:0.010311:0.009903:0.005866:0.005866:0.003024:0.010311:0.003024:0.009827:0.004188:0.004188:0.002948:0.008104:0.007257:0.009782:0.009827:0.003024:0.003024:0.009827:0.009223:0.005125:0.004188
glycaemic control with agents that have been shown :@0.519047:0.375989:0.928017:0.375989:0.928017:0.360207:0.519047:0.360207:0.010175:0.003024:0.008104:0.009782:0.010326:0.009827:0.014182:0.003024:0.009782:0.005866:0.009782:0.009903:0.009223:0.005125:0.004551:0.009903:0.003024:0.005851:0.012564:0.003024:0.005125:0.009223:0.005866:0.010326:0.010175:0.009827:0.009223:0.005125:0.005866:0.005866:0.005125:0.009223:0.010326:0.005125:0.005866:0.009223:0.010326:0.008376:0.009827:0.005866:0.010311:0.009827:0.009827:0.009223:0.005866:0.005866:0.009223:0.009903:0.012564:0.009223:0.004188
to reduce cardiovascular risk must be the treatment of :@0.519047:0.390225:0.927987:0.390225:0.927987:0.374442:0.519047:0.374442:0.005125:0.009903:0.004883:0.004551:0.009827:0.010357:0.009192:0.009782:0.009827:0.004883:0.009782:0.010326:0.004551:0.010357:0.003024:0.009903:0.008376:0.010326:0.005866:0.009782:0.009192:0.003024:0.010326:0.004551:0.004899:0.004551:0.003024:0.005866:0.007590:0.004899:0.014182:0.009192:0.005866:0.005125:0.004899:0.010311:0.009827:0.004899:0.005125:0.009223:0.009827:0.004883:0.005125:0.004551:0.009827:0.010326:0.005125:0.014182:0.009827:0.009223:0.005125:0.004883:0.009903:0.004747:0.004188
choice. All risk factors must be addressed, although the :@0.519047:0.404461:0.928002:0.404461:0.928002:0.388678:0.519047:0.388678:0.009782:0.009223:0.009903:0.003024:0.009782:0.009827:0.004188:0.004248:0.011188:0.003024:0.003024:0.004264:0.004551:0.003024:0.005866:0.007590:0.004264:0.004747:0.010326:0.009782:0.005125:0.009903:0.004551:0.005866:0.004264:0.014182:0.009192:0.005866:0.005125:0.004264:0.010311:0.009827:0.004264:0.010326:0.010357:0.010357:0.004551:0.009827:0.005866:0.005866:0.009827:0.010357:0.004188:0.004264:0.010326:0.003024:0.005125:0.009223:0.009903:0.009192:0.010175:0.009223:0.004248:0.005125:0.009223:0.009827:0.004188
essential aspect of care remains good communication :@0.519047:0.418696:0.927987:0.418696:0.927987:0.402913:0.519047:0.402913:0.009827:0.005866:0.005866:0.009827:0.009223:0.005125:0.003024:0.010326:0.003024:0.004687:0.010326:0.005866:0.010311:0.009827:0.009782:0.005125:0.004672:0.009903:0.004747:0.004672:0.009782:0.010326:0.004551:0.009827:0.004672:0.004551:0.009827:0.014182:0.010326:0.003024:0.009223:0.005866:0.004687:0.010175:0.009903:0.009903:0.010357:0.004672:0.009782:0.009903:0.014182:0.014182:0.009192:0.009223:0.003024:0.009782:0.010326:0.005125:0.003024:0.009903:0.009223:0.004188
with, and support of, patients to enable and empower :@0.519047:0.432932:0.928017:0.432932:0.928017:0.417149:0.519047:0.417149:0.012564:0.003024:0.005125:0.009223:0.004188:0.004899:0.010326:0.009223:0.010357:0.004899:0.005866:0.009192:0.010311:0.010311:0.009903:0.004551:0.005125:0.004899:0.009903:0.004747:0.004188:0.004899:0.010311:0.010326:0.005125:0.003024:0.009827:0.009223:0.005125:0.005866:0.004899:0.005125:0.009903:0.004899:0.009827:0.009223:0.010326:0.010311:0.003024:0.009827:0.004899:0.010326:0.009223:0.010357:0.004899:0.009827:0.014182:0.010311:0.009903:0.012564:0.009827:0.004551:0.004188
them to look after their health.:@0.519047:0.447167:0.741055:0.447167:0.741055:0.431385:0.519047:0.431385:0.005125:0.009223:0.009827:0.014182:0.004188:0.005125:0.009903:0.004188:0.003024:0.009903:0.009903:0.007590:0.004188:0.010326:0.004747:0.005125:0.009827:0.004551:0.004188:0.005125:0.009223:0.009827:0.003024:0.004551:0.004188:0.009223:0.009827:0.010326:0.003024:0.005125:0.009223:0.004188
referenCes:@0.519047:0.480203:0.625485:0.480203:0.625485:0.460038:0.519047:0.460038:0.010718:0.009609:0.008870:0.009609:0.010718:0.009609:0.013674:0.014413:0.009609:0.009609
1. :@0.519047:0.492226:0.532076:0.492226:0.532076:0.479951:0.519047:0.479951:0.006515:0.003257:0.003257
shisana O,  Labadarios D,  Rehle  T, :@0.544247:0.492226:0.750328:0.492226:0.750328:0.479951:0.544247:0.479951:0.005856:0.007173:0.002352:0.004563:0.008032:0.007173:0.008032:0.006044:0.010219:0.003257:0.003257:0.002775:0.005433:0.008032:0.008020:0.008032:0.008055:0.008032:0.003540:0.002352:0.007702:0.004563:0.006044:0.008749:0.003257:0.003257:0.002775:0.007138:0.007644:0.007173:0.002352:0.007644:0.003257:0.002775:0.005009:0.003257:0.003257
et  al:@0.753103:0.492226:0.781149:0.492226:0.781149:0.479951:0.753103:0.479951:0.007644:0.003986:0.003257:0.002775:0.008032:0.002352
.  south  African  National :@0.781149:0.492226:0.927070:0.492226:0.927070:0.479951:0.781149:0.479951:0.003257:0.003257:0.002787:0.005856:0.007702:0.007150:0.003986:0.007173:0.003257:0.002775:0.008702:0.003692:0.003540:0.002352:0.007608:0.008032:0.007173:0.003257:0.002775:0.008702:0.008032:0.003986:0.002352:0.007702:0.007173:0.008032:0.002352:0.003257
Health and Nutrition  Examination  survey, 2012. 2014  ed.  Cape :@0.544247:0.503262:0.927064:0.503259:0.927064:0.490984:0.544247:0.490987:0.008032:0.007644:0.008032:0.002352:0.003986:0.007173:0.006009:0.008032:0.007173:0.008055:0.006009:0.008702:0.007150:0.003986:0.003540:0.002352:0.003986:0.002352:0.007691:0.007173:0.003257:0.002740:0.006303:0.005644:0.008032:0.011030:0.002352:0.007173:0.008032:0.003986:0.002352:0.007702:0.007173:0.003257:0.002752:0.005856:0.007150:0.003540:0.006515:0.007644:0.006303:0.003257:0.006009:0.006515:0.006515:0.006515:0.006515:0.003257:0.006009:0.006515:0.006515:0.006515:0.006515:0.006474:0.006009:0.007644:0.008055:0.003257:0.003257:0.002740:0.009560:0.008032:0.008020:0.007644:-0.257238
th:@0.853119:0.499138:0.859591:0.499138:0.859591:0.492018:0.853119:0.492018:0.002312:0.004160
Town HsRC press; 2014:1-397.:@0.544241:0.514295:0.708377:0.514295:0.708377:0.502020:0.544241:0.502020:0.005009:0.007702:0.009772:0.007173:0.003257:0.008032:0.005856:0.007138:0.009560:0.003257:0.008020:0.003540:0.007644:0.004563:0.004563:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257
2. :@0.519041:0.525331:0.532071:0.525331:0.532071:0.513056:0.519041:0.513056:0.006515:0.003257:0.003257
International Diabetes Federation. :@0.544241:0.525331:0.741891:0.525331:0.741891:0.513056:0.544241:0.513056:0.002658:0.007173:0.003986:0.007644:0.003540:0.007173:0.008032:0.003986:0.002352:0.007702:0.007173:0.008032:0.002352:0.003257:0.008749:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.005703:0.007644:0.008055:0.007644:0.003540:0.008032:0.003986:0.002352:0.007702:0.007173:0.003257:0.003257
IDF Diabetes Atlas:@0.741879:0.525331:0.844126:0.525331:0.844126:0.513056:0.741879:0.513056:0.002658:0.008749:0.005703:0.003257:0.008749:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.008702:0.003986:0.002352:0.008032:0.004563
, 7th ed. 2015.:@0.844126:0.525331:0.923101:0.525331:0.923101:0.513056:0.844126:0.513056:0.003257:0.003257:0.006515:0.003986:0.007173:0.003257:0.007644:0.008055:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257
3. :@0.519053:0.536368:0.532082:0.536368:0.532082:0.524092:0.519053:0.524092:0.006515:0.003257:0.003257
sEMDsA 2017 Guidelines for the management of type 2 diabetes :@0.544253:0.536368:0.927064:0.536368:0.927064:0.524092:0.544253:0.524092:0.005856:0.006303:0.010807:0.008749:0.005856:0.008702:0.004457:0.006515:0.006515:0.006515:0.006515:0.004469:0.010254:0.007150:0.002352:0.008055:0.007644:0.002352:0.002352:0.007173:0.007644:0.004563:0.004469:0.003692:0.007702:0.003540:0.004457:0.003986:0.007173:0.007644:0.004457:0.011030:0.008032:0.007173:0.008032:0.007914:0.007644:0.011030:0.007644:0.007173:0.003986:0.004457:0.007702:0.003692:0.004457:0.003986:0.006303:0.008020:0.007644:0.004457:0.006515:0.004457:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257
mellitus. :@0.544253:0.547404:0.592196:0.547404:0.592196:0.535128:0.544253:0.535128:0.011030:0.007644:0.002352:0.002352:0.002352:0.003986:0.007150:0.004563:0.003257:0.003257
JEMDSA.:@0.592196:0.547404:0.641538:0.547404:0.641538:0.535128:0.592196:0.535128:0.005668:0.006303:0.010807:0.008749:0.005856:0.008702:0.003257
 2017;22(1): s1-s196.:@0.641538:0.547404:0.753780:0.547404:0.753780:0.535128:0.641538:0.535128:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.004339:0.006515:0.004339:0.003257:0.003257:0.005856:0.006515:0.003904:0.005856:0.006515:0.006515:0.006515:0.003257
4. :@0.519053:0.558440:0.532082:0.558440:0.532082:0.546165:0.519053:0.546165:0.006515:0.003257:0.003257
Bangalore s, Fakheri R, Toklu B:@0.544253:0.558440:0.720560:0.558440:0.720560:0.546165:0.544253:0.546165:0.006750:0.008032:0.007173:0.007914:0.008032:0.002352:0.007702:0.003540:0.007644:0.004492:0.005856:0.003257:0.004492:0.005703:0.008032:0.005903:0.007173:0.007644:0.003540:0.002352:0.004492:0.007138:0.003257:0.004492:0.005009:0.007702:0.005903:0.002352:0.007150:0.004480:0.006750
, et al:@0.720560:0.558440:0.754814:0.558440:0.754814:0.546165:0.720560:0.546165:0.003257:0.004492:0.007644:0.003986:0.004492:0.008032:0.002352
. Diabetes mellitus as a com-:@0.754814:0.558440:0.923818:0.558440:0.923818:0.546165:0.754814:0.546165:0.003257:0.004492:0.008749:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.004492:0.011030:0.007644:0.002352:0.002352:0.002352:0.003986:0.007150:0.004563:0.004492:0.008032:0.004563:0.004492:0.008032:0.004492:0.007608:0.007702:0.011030:0.003904
pelling indication for the use of renin angiotensin system blockers: :@0.544253:0.569476:0.927087:0.569476:0.927087:0.557201:0.544253:0.557201:0.008020:0.007644:0.002352:0.002352:0.002352:0.007173:0.007914:0.004210:0.002352:0.007173:0.008055:0.002352:0.007608:0.008032:0.003986:0.002352:0.007702:0.007173:0.004210:0.003692:0.007702:0.003540:0.004210:0.003986:0.007173:0.007644:0.004210:0.007150:0.004563:0.007644:0.004210:0.007702:0.003692:0.004210:0.003540:0.007644:0.007173:0.002352:0.007173:0.004198:0.008032:0.007173:0.007914:0.002352:0.007702:0.003986:0.007644:0.007173:0.004563:0.002352:0.007173:0.004210:0.004563:0.006303:0.004563:0.003986:0.007644:0.011030:0.004210:0.008020:0.002352:0.007702:0.007608:0.005903:0.007644:0.003540:0.004563:0.003257:0.003257
systematic review  and  meta-analysis  of  randomized  trials. :@0.544253:0.580512:0.894162:0.580512:0.894162:0.568237:0.544253:0.568237:0.005856:0.006303:0.004563:0.003986:0.007644:0.011030:0.008032:0.003986:0.002352:0.007608:0.006432:0.003540:0.007644:0.006515:0.002352:0.007644:0.009772:0.003257:0.003163:0.008032:0.007173:0.008055:0.003257:0.003163:0.011030:0.007644:0.003986:0.008032:0.003904:0.008032:0.007173:0.008032:0.002352:0.006303:0.004563:0.002352:0.004574:0.003257:0.003163:0.007702:0.003692:0.003257:0.003163:0.003540:0.008032:0.007173:0.008055:0.007702:0.011030:0.002352:0.004998:0.007644:0.008055:0.003257:0.003163:0.003986:0.003540:0.002352:0.008032:0.002352:0.004563:0.003257:0.003257
BMJ. :@0.897337:0.580512:0.927076:0.580512:0.927076:0.568237:0.897337:0.568237:0.006750:0.010807:0.005668:0.003257:0.003257
2:@0.544253:0.591548:0.550768:0.591548:0.550768:0.579273:0.544253:0.579273:0.006515
016;352:438:@0.550768:0.591548:0.615914:0.591548:0.615914:0.579273:0.550768:0.579273:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515
5. :@0.519053:0.602585:0.532082:0.602585:0.532082:0.590309:0.519053:0.590309:0.006515:0.003257:0.003257
UKpDs tight blood pressure control and risk of macrovascular and :@0.544253:0.602585:0.927076:0.602585:0.927076:0.590309:0.544253:0.590309:0.007702:0.006950:0.006961:0.008749:0.005856:0.004151:0.003986:0.002352:0.007914:0.007173:0.003986:0.004151:0.008020:0.002352:0.007702:0.007702:0.008055:0.004163:0.008020:0.003540:0.007644:0.004563:0.004563:0.007150:0.003540:0.007644:0.004151:0.007608:0.007702:0.007173:0.003986:0.003540:0.007702:0.002352:0.004151:0.008032:0.007173:0.008055:0.004163:0.003540:0.002352:0.004563:0.005903:0.004163:0.007702:0.003692:0.004151:0.011030:0.008032:0.007608:0.003540:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.004163:0.008032:0.007173:0.008055:0.003257
microvascular complications in type 2 diabetes mellitus. UKpDs 38. :@0.544253:0.613621:0.927076:0.613621:0.927076:0.601345:0.544253:0.601345:0.011030:0.002352:0.007608:0.003540:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.003692:0.007608:0.007702:0.011030:0.008020:0.002352:0.002352:0.007608:0.008032:0.003986:0.002352:0.007702:0.007173:0.004563:0.003704:0.002352:0.007173:0.003692:0.003986:0.006303:0.008020:0.007644:0.003692:0.006515:0.003704:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003704:0.011030:0.007644:0.002352:0.002352:0.002352:0.003986:0.007150:0.004563:0.003257:0.003704:0.007702:0.006950:0.006961:0.008749:0.005856:0.003692:0.006515:0.006515:0.003257:0.003257
BMJ.:@0.544253:0.624657:0.570735:0.624657:0.570735:0.612382:0.544253:0.612382:0.006750:0.010807:0.005668:0.003257
 1998;(317)703-713.:@0.570735:0.624657:0.677780:0.624657:0.677780:0.612382:0.570735:0.612382:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.004339:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257
6. :@0.519053:0.635693:0.532082:0.635693:0.532082:0.623418:0.519053:0.623418:0.006515:0.003257:0.003257
spRINT trial research group. A randomized trial of intensive versus :@0.544253:0.635693:0.927064:0.635693:0.927064:0.623418:0.544253:0.623418:0.005856:0.006961:0.007138:0.002658:0.008702:0.005009:0.004810:0.003986:0.003540:0.002352:0.008032:0.002352:0.004821:0.003540:0.007644:0.004563:0.007644:0.008032:0.003540:0.007608:0.007173:0.004810:0.007914:0.003540:0.007702:0.007150:0.008020:0.003257:0.004810:0.008702:0.004810:0.003540:0.008032:0.007173:0.008055:0.007702:0.011030:0.002352:0.004998:0.007644:0.008055:0.004810:0.003986:0.003540:0.002352:0.008032:0.002352:0.004821:0.007702:0.003692:0.004821:0.002352:0.007173:0.003986:0.007644:0.007173:0.004563:0.002352:0.006515:0.007644:0.004821:0.006515:0.007644:0.003540:0.004563:0.007150:0.004563:0.003257
standard blood-pressure control. :@0.544253:0.646729:0.733177:0.646729:0.733177:0.634454:0.544253:0.634454:0.004563:0.003986:0.008032:0.007173:0.008055:0.008032:0.003540:0.008055:0.003257:0.008020:0.002352:0.007702:0.007702:0.008055:0.003904:0.008020:0.003540:0.007644:0.004563:0.004563:0.007150:0.003540:0.007644:0.003257:0.007608:0.007702:0.007173:0.003986:0.003540:0.007702:0.002352:0.003257:0.003257
N Engl J Med.:@0.733154:0.646729:0.810800:0.646729:0.810800:0.634454:0.733154:0.634454:0.008702:0.003257:0.006303:0.007173:0.007914:0.002352:0.003257:0.005668:0.003257:0.010807:0.007644:0.008055:0.003257
 Epub 2015 Nov 9.:@0.810788:0.646729:0.912059:0.646729:0.912059:0.634454:0.810788:0.634454:0.003257:0.006303:0.008020:0.007150:0.008020:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.008702:0.007702:0.006515:0.003257:0.006515:0.003257
7. :@0.519053:0.657765:0.532082:0.657765:0.532082:0.645490:0.519053:0.645490:0.006515:0.003257:0.003257
Zelniker TA, :@0.544253:0.657765:0.611528:0.657765:0.611528:0.645490:0.544253:0.645490:0.005644:0.007644:0.002352:0.007173:0.002352:0.005903:0.007644:0.003540:0.004810:0.005009:0.008690:0.003257:0.003257
et al:@0.613080:0.657765:0.639903:0.657765:0.639903:0.645490:0.613080:0.645490:0.007644:0.003986:0.004810:0.008032:0.002352
. sGLT2 inhibitors for primary and secondary pre-:@0.639903:0.657765:0.923842:0.657765:0.923842:0.645490:0.639903:0.645490:0.003257:0.004810:0.005856:0.010254:0.005433:0.005009:0.006515:0.004810:0.002352:0.007173:0.007173:0.002352:0.008020:0.002352:0.003986:0.007702:0.003540:0.004563:0.004810:0.003692:0.007702:0.003540:0.004810:0.008020:0.003540:0.002352:0.011030:0.008032:0.003540:0.006303:0.004810:0.008032:0.007173:0.008055:0.004810:0.004563:0.007644:0.007608:0.007702:0.007173:0.008055:0.008032:0.003540:0.006303:0.004810:0.008020:0.003540:0.007644:0.003904
vention of cardiovascular and renal outcomes in type 2 diabetes: :@0.544253:0.668802:0.927087:0.668802:0.927087:0.656526:0.544253:0.656526:0.006515:0.007644:0.007173:0.003986:0.002352:0.007702:0.007173:0.003951:0.007702:0.003692:0.003963:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.003963:0.008032:0.007173:0.008055:0.003963:0.003540:0.007644:0.007173:0.008032:0.002352:0.003951:0.007702:0.007150:0.003986:0.007608:0.007702:0.011030:0.007644:0.004563:0.003951:0.002352:0.007173:0.003963:0.003986:0.006303:0.008020:0.007644:0.003963:0.006515:0.003963:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.003257
A systematic review and meta-analysis of cardiovascular outcome :@0.544253:0.679838:0.927076:0.679838:0.927076:0.667562:0.544253:0.667562:0.008702:0.003257:0.004563:0.006303:0.004563:0.003986:0.007644:0.011030:0.008032:0.003986:0.002352:0.007608:0.003257:0.003540:0.007644:0.006515:0.002352:0.007644:0.009772:0.003257:0.008032:0.007173:0.008055:0.003257:0.011030:0.007644:0.003986:0.008032:0.003904:0.008032:0.007173:0.008032:0.002352:0.006303:0.004563:0.002352:0.004563:0.003269:0.007702:0.003692:0.003257:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.003257:0.007702:0.007150:0.003986:0.007608:0.007702:0.011030:0.007644:0.003257
trials. :@0.544253:0.690874:0.575592:0.690874:0.575592:0.678599:0.544253:0.678599:0.003986:0.003540:0.002352:0.008032:0.002352:0.004563:0.003257:0.003257
Lancet:@0.575592:0.690874:0.615467:0.690874:0.615467:0.678599:0.575592:0.678599:0.005433:0.008032:0.007173:0.007608:0.007644:0.003986
. 2019 Jan 5;393(10166):31-39. :@0.615467:0.690874:0.785729:0.690874:0.785729:0.678599:0.615467:0.678599:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.005668:0.008032:0.007173:0.003257:0.006515:0.003257:0.006515:0.006515:0.006515:0.004339:0.006515:0.006515:0.006515:0.006515:0.006515:0.004339:0.003257:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257:0.003257
8. :@0.519053:0.701910:0.532082:0.701910:0.532082:0.689635:0.519053:0.689635:0.006515:0.003257:0.003257
Marso sp, :@0.544253:0.701910:0.601932:0.701910:0.601932:0.689635:0.544253:0.689635:0.010807:0.008032:0.003540:0.004563:0.007702:0.003704:0.005856:0.006961:0.003257:0.003257
et al:@0.602379:0.701910:0.628097:0.701910:0.628097:0.689635:0.602379:0.689635:0.007644:0.003986:0.003704:0.008032:0.002352
. Liraglutide and cardiovascular outcomes in type 2 :@0.628097:0.701910:0.927052:0.701910:0.927052:0.689635:0.628097:0.689635:0.003257:0.003704:0.005433:0.002352:0.003540:0.008032:0.007914:0.002352:0.007150:0.003986:0.002352:0.008055:0.007644:0.003704:0.008032:0.007173:0.008055:0.003704:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.003704:0.007702:0.007150:0.003986:0.007608:0.007702:0.011030:0.007644:0.004563:0.003692:0.002352:0.007173:0.003704:0.003986:0.006303:0.008020:0.007644:0.003704:0.006515:0.003257
diabetes. :@0.544253:0.712946:0.601062:0.712946:0.601062:0.700671:0.544253:0.700671:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.003257
N Engl J Med:@0.601062:0.712946:0.675451:0.712946:0.675451:0.700671:0.601062:0.700671:0.008702:0.003257:0.006303:0.007173:0.007914:0.002352:0.003257:0.005668:0.003257:0.010807:0.007644:0.008055
 2016; 375:311-322.:@0.675439:0.712946:0.780320:0.712946:0.780320:0.700671:0.675439:0.700671:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257
9. :@0.519053:0.723982:0.532082:0.723982:0.532082:0.711707:0.519053:0.711707:0.006515:0.003257:0.003257
White WB, :@0.544253:0.723982:0.606177:0.723982:0.606177:0.711707:0.544253:0.711707:0.011289:0.007173:0.002352:0.003986:0.007644:0.004927:0.011289:0.006750:0.003257:0.003257
et al. :@0.607847:0.723982:0.641302:0.723982:0.641302:0.711707:0.607847:0.711707:0.007644:0.003986:0.004927:0.008032:0.002352:0.003257:0.003257
Alogliptin after acute coronary syndrome in pa-:@0.642972:0.723982:0.923830:0.723982:0.923830:0.711707:0.642972:0.711707:0.008702:0.002352:0.007702:0.007914:0.002352:0.002352:0.008020:0.003986:0.002352:0.007173:0.004927:0.008032:0.003692:0.003986:0.007644:0.003540:0.004927:0.008032:0.007608:0.007150:0.003986:0.007644:0.004927:0.007608:0.007702:0.003540:0.007702:0.007173:0.008032:0.003540:0.006303:0.004915:0.004563:0.006303:0.007173:0.008055:0.003540:0.007702:0.011030:0.007644:0.004927:0.002352:0.007173:0.004927:0.008020:0.008032:0.003904
tients with type 2 diabetes. :@0.544253:0.735019:0.699546:0.735019:0.699546:0.722743:0.544253:0.722743:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.003257:0.009772:0.002352:0.003986:0.007173:0.003257:0.003986:0.006303:0.008020:0.007644:0.003257:0.006515:0.003257:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.003257
N Engl J Med:@0.699546:0.735019:0.773935:0.735019:0.773935:0.722743:0.699546:0.722743:0.008702:0.003257:0.006303:0.007173:0.007914:0.002352:0.003257:0.005668:0.003257:0.010807:0.007644:0.008055
 2013; 369:1327-1335.:@0.773923:0.735019:0.891833:0.735019:0.891833:0.722743:0.773923:0.722743:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515:0.003257
10.  scirica BM, :@0.519053:0.746055:0.604555:0.746055:0.604555:0.733779:0.519053:0.733779:0.006162:0.006162:0.002905:0.003257:0.006715:0.005503:0.007255:0.001999:0.003187:0.001999:0.007255:0.007679:0.002411:0.006397:0.010454:0.002905:0.003257
et al:@0.603720:0.746055:0.627085:0.746055:0.627085:0.733779:0.603720:0.733779:0.007291:0.003634:0.002411:0.007679:0.002352
. Insulin and glucose-lowering agents for treating people :@0.626733:0.746055:0.927052:0.746055:0.927052:0.733779:0.626733:0.733779:0.002905:0.002411:0.002305:0.006820:0.004210:0.006797:0.001999:0.001999:0.006820:0.002411:0.007679:0.006820:0.007702:0.002411:0.007561:0.001999:0.006797:0.007255:0.007350:0.004210:0.007291:0.003551:0.001999:0.007350:0.009419:0.007291:0.003187:0.001999:0.006820:0.007561:0.002411:0.007679:0.007561:0.007291:0.006820:0.003634:0.004210:0.002411:0.003340:0.007350:0.003187:0.002411:0.003634:0.003187:0.007291:0.007679:0.003634:0.001999:0.006820:0.007561:0.002411:0.007667:0.007291:0.007350:0.007667:0.001999:0.007644:0.003257
with diabetes and chronic disease. :@0.544253:0.757091:0.734647:0.757091:0.734647:0.744816:0.544253:0.744816:0.009419:0.001999:0.003634:0.006820:0.002905:0.007702:0.001999:0.007679:0.007667:0.007291:0.003634:0.007291:0.004210:0.002905:0.007679:0.006820:0.007702:0.002905:0.007255:0.006820:0.003187:0.007350:0.006820:0.001999:0.007255:0.002905:0.007702:0.001999:0.004210:0.007291:0.007679:0.004210:0.007291:0.002905:0.003257
N Engl J Med.:@0.734295:0.757091:0.807708:0.757091:0.807708:0.744816:0.734295:0.744816:0.008349:0.002905:0.005950:0.006820:0.007561:0.001999:0.002905:0.005315:0.002905:0.010454:0.007291:0.007702:0.003257
 2013; 369: 1317-1326.:@0.807355:0.757091:0.921114:0.757091:0.921114:0.744816:0.807355:0.744816:0.002905:0.006162:0.006162:0.006162:0.006162:0.002905:0.002905:0.006162:0.006162:0.006162:0.002905:0.002905:0.006162:0.006162:0.006162:0.006162:0.003551:0.006162:0.006162:0.006162:0.006162:0.003257
11.  Green JB, :@0.519053:0.768127:0.603249:0.768127:0.603249:0.755852:0.519053:0.755852:0.006515:0.006515:0.003257:0.003257:0.005656:0.010254:0.003540:0.007644:0.007644:0.007173:0.003810:0.005668:0.006750:0.003257:0.003257
et al:@0.603802:0.768127:0.629625:0.768127:0.629625:0.755852:0.603802:0.755852:0.007644:0.003986:0.003810:0.008032:0.002352
. Effect of sitagliptin on cardiovascular outcomes in :@0.629625:0.768127:0.927087:0.768127:0.927087:0.755852:0.629625:0.755852:0.003257:0.003810:0.006303:0.003692:0.003692:0.007644:0.007608:0.003986:0.003810:0.007702:0.003692:0.003810:0.004563:0.002352:0.003986:0.008032:0.007914:0.002352:0.002352:0.008020:0.003986:0.002352:0.007173:0.003822:0.007702:0.007173:0.003810:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008043:0.003540:0.003810:0.007702:0.007150:0.003986:0.007608:0.007702:0.011030:0.007644:0.004563:0.003798:0.002352:0.007173:0.003257
type 2 diabetes. :@0.544253:0.779163:0.640044:0.779163:0.640044:0.766888:0.544253:0.766888:0.003986:0.006303:0.008020:0.007644:0.003257:0.006515:0.003257:0.008055:0.002352:0.008032:0.008020:0.007644:0.003986:0.007644:0.004563:0.003257:0.003257
N Engl J Med.:@0.640044:0.779163:0.717690:0.779163:0.717690:0.766888:0.640044:0.766888:0.008702:0.003257:0.006303:0.007173:0.007914:0.002352:0.003257:0.005668:0.003257:0.010807:0.007644:0.008055:0.003257
 2015 ; 373:232-242.:@0.717679:0.779163:0.825817:0.779163:0.825817:0.766888:0.717679:0.766888:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257
12.  McMurray JJV, :@0.519053:0.790199:0.632401:0.790199:0.632401:0.777924:0.519053:0.777924:0.006515:0.006515:0.003257:0.003257:0.005656:0.010807:0.007608:0.010807:0.007150:0.003540:0.003540:0.008032:0.006303:0.004257:0.005668:0.005668:0.008255:0.003257:0.003257
et al.:@0.633400:0.790199:0.662928:0.790199:0.662928:0.777924:0.633400:0.777924:0.007644:0.003986:0.004257:0.008032:0.002352:0.003257
 Angiotensin-neprilysin inhibition versus enala-:@0.662928:0.790199:0.923807:0.790199:0.923807:0.777924:0.662928:0.777924:0.004257:0.008702:0.007173:0.007914:0.002352:0.007702:0.003986:0.007644:0.007173:0.004563:0.002352:0.007173:0.003904:0.007173:0.007644:0.008020:0.003540:0.002352:0.002352:0.006303:0.004563:0.002352:0.007173:0.004257:0.002352:0.007173:0.007173:0.002352:0.008020:0.002352:0.003986:0.002352:0.007702:0.007173:0.004257:0.006515:0.007644:0.003540:0.004563:0.007150:0.004563:0.004257:0.007644:0.007173:0.008032:0.002352:0.008032:0.003904
pril in heart failure. :@0.544253:0.801236:0.651462:0.801236:0.651462:0.788960:0.544253:0.788960:0.008020:0.003540:0.002352:0.002352:0.003257:0.002352:0.007173:0.003257:0.007173:0.007644:0.008032:0.003540:0.003986:0.003257:0.003692:0.008032:0.002352:0.002352:0.007150:0.003540:0.007644:0.003257:0.003257
N Engl J Med. :@0.651451:0.801236:0.732354:0.801236:0.732354:0.788960:0.651451:0.788960:0.008702:0.003257:0.006303:0.007173:0.007914:0.002352:0.003257:0.005668:0.003257:0.010807:0.007644:0.008055:0.003257:0.003257
2014:371:993-1004.:@0.732342:0.801236:0.837223:0.801236:0.837223:0.788960:0.732342:0.788960:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515:0.003257
13.  packer M. Angiotensin receptor neprilysin inhibition compared with :@0.519053:0.812272:0.927076:0.812272:0.927076:0.799996:0.519053:0.799996:0.006515:0.006515:0.003257:0.003257:0.005656:0.006961:0.008032:0.007608:0.005903:0.007644:0.003540:0.003199:0.010807:0.003257:0.003199:0.008702:0.007173:0.007914:0.002352:0.007702:0.003986:0.007644:0.007173:0.004563:0.002352:0.007173:0.003187:0.003540:0.007644:0.007608:0.007644:0.008020:0.003986:0.007702:0.003540:0.003187:0.007173:0.007644:0.008020:0.003540:0.002352:0.002352:0.006303:0.004563:0.002352:0.007173:0.003210:0.002352:0.007173:0.007173:0.002352:0.008020:0.002352:0.003986:0.002352:0.007702:0.007173:0.003199:0.007608:0.007702:0.011030:0.008020:0.008032:0.003540:0.007644:0.008055:0.003199:0.009772:0.002352:0.003986:0.007173:0.003257
enalapril on the risk of clinical progression in surviving patients with :@0.544253:0.823308:0.927076:0.823308:0.927076:0.811033:0.544253:0.811033:0.007644:0.007173:0.008032:0.002352:0.008032:0.008020:0.003540:0.002352:0.002352:0.003751:0.007702:0.007173:0.003739:0.003986:0.007173:0.007644:0.003739:0.003540:0.002352:0.004563:0.005903:0.003751:0.007702:0.003692:0.003739:0.007608:0.002352:0.002352:0.007173:0.002352:0.007608:0.008032:0.002352:0.003751:0.008020:0.003540:0.007702:0.007914:0.003540:0.007644:0.004563:0.004563:0.002352:0.007702:0.007173:0.003739:0.002352:0.007173:0.003751:0.004563:0.007150:0.003540:0.006515:0.002352:0.006515:0.002352:0.007173:0.007914:0.003751:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.003751:0.009772:0.002352:0.003986:0.007173:0.003257
heart failure. :@0.544253:0.834344:0.619160:0.834344:0.619160:0.822069:0.544253:0.822069:0.007173:0.007644:0.008032:0.003540:0.003986:0.003257:0.003692:0.008032:0.002352:0.002352:0.007150:0.003540:0.007644:0.003257:0.003257
Circulation.:@0.619148:0.834344:0.684212:0.834344:0.684212:0.822069:0.619148:0.822069:0.009560:0.002352:0.003540:0.007608:0.007150:0.002352:0.008032:0.003986:0.002352:0.007702:0.007173:0.003257
 2015;131:54-61.:@0.684212:0.834344:0.772806:0.834344:0.772806:0.822069:0.684212:0.822069:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003904:0.006515:0.006515:0.003257
14.  ponikowski p. 2016 EsC Guidelines for the diagnosis and treatment :@0.519053:0.845380:0.927087:0.845380:0.927087:0.833105:0.519053:0.833105:0.006515:0.006515:0.003257:0.003257:0.005656:0.006961:0.007702:0.007173:0.002352:0.005903:0.007702:0.009772:0.004563:0.005903:0.002352:0.003881:0.006961:0.003257:0.003881:0.006515:0.006515:0.006515:0.006515:0.003892:0.006303:0.005856:0.009560:0.003881:0.010254:0.007150:0.002352:0.008055:0.007644:0.002352:0.002352:0.007173:0.007644:0.004563:0.003881:0.003692:0.007702:0.003540:0.003881:0.003986:0.007173:0.007644:0.003881:0.008055:0.002352:0.008032:0.007914:0.007173:0.007702:0.004563:0.002352:0.004563:0.003881:0.008032:0.007173:0.008055:0.003881:0.003986:0.003540:0.007644:0.008032:0.003986:0.011030:0.007644:0.007173:0.003986:0.003257
of acute and chronic heart failure. :@0.544253:0.856416:0.744419:0.856416:0.744419:0.844141:0.544253:0.844141:0.007702:0.003692:0.003257:0.008032:0.007608:0.007150:0.003986:0.007644:0.003257:0.008032:0.007173:0.008055:0.003257:0.007608:0.007173:0.003540:0.007702:0.007173:0.002352:0.007608:0.003257:0.007173:0.007644:0.008032:0.003540:0.003986:0.003257:0.003692:0.008032:0.002352:0.002352:0.007150:0.003540:0.007644:0.003257:0.003257
Eur Heart J:@0.744396:0.856416:0.804803:0.856416:0.804803:0.844141:0.744396:0.844141:0.006303:0.007150:0.003540:0.003257:0.008032:0.007644:0.008032:0.003540:0.003986:0.003257:0.005668
. 2016;18:891-975.:@0.804791:0.856416:0.903157:0.856416:0.903157:0.844141:0.804791:0.844141:0.003257:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.003257
15.  Grundy sM, :@0.519053:0.867453:0.613186:0.867453:0.613186:0.855177:0.519053:0.855177:0.006515:0.006515:0.003257:0.003257:0.005656:0.010254:0.003540:0.007150:0.007173:0.008055:0.006303:0.003281:0.005856:0.010807:0.003257:0.003257
et al:@0.613210:0.867453:0.638504:0.867453:0.638504:0.855177:0.613210:0.855177:0.007644:0.003986:0.003281:0.008032:0.002352
. Guidelines on the management of blood choles-:@0.638504:0.867453:0.923783:0.867453:0.923783:0.855177:0.638504:0.855177:0.003257:0.003281:0.010254:0.007150:0.002352:0.008055:0.007644:0.002352:0.002352:0.007173:0.007644:0.004563:0.003293:0.007702:0.007173:0.003281:0.003986:0.007173:0.007644:0.003281:0.011030:0.008032:0.007173:0.008032:0.007914:0.007644:0.011030:0.007644:0.007173:0.003986:0.003281:0.007702:0.003692:0.003281:0.008020:0.002352:0.007702:0.007702:0.008055:0.003281:0.007608:0.007173:0.007702:0.002352:0.007644:0.004563:0.003904
terol. :@0.544241:0.878489:0.575980:0.878489:0.575980:0.866213:0.544241:0.866213:0.003986:0.007644:0.003540:0.007702:0.002352:0.003257:0.003257
Circulation.:@0.575968:0.878489:0.641032:0.878489:0.641032:0.866213:0.575968:0.866213:0.009560:0.002352:0.003540:0.007608:0.007150:0.002352:0.008032:0.003986:0.002352:0.007702:0.007173:0.003257
 2018; 139:1082-1143. :@0.641032:0.878489:0.762199:0.878489:0.762199:0.866213:0.641032:0.866213:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257
16.  schwartz  GG, :@0.519041:0.889525:0.628144:0.889525:0.628144:0.877250:0.519041:0.877250:0.006515:0.006515:0.003257:0.003257:0.005656:0.005856:0.007608:0.007173:0.009772:0.008032:0.003540:0.003986:0.004998:0.003257:0.002658:0.010254:0.010254:0.003257:0.003257
et  al:@0.630801:0.889525:0.658730:0.889525:0.658730:0.877250:0.630801:0.877250:0.007644:0.003986:0.003257:0.002658:0.008032:0.002352
.    Alirocumab  and  cardiovascular outcomes :@0.658730:0.889525:0.927040:0.889525:0.927040:0.877250:0.658730:0.877250:0.003257:0.003257:0.002658:0.003257:0.002658:0.008702:0.002352:0.002352:0.003540:0.007702:0.007608:0.007150:0.011030:0.008032:0.008020:0.003257:0.002658:0.008032:0.007173:0.008055:0.003257:0.002658:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.005927:0.007702:0.007150:0.003986:0.007608:0.007702:0.011030:0.007644:0.004563:0.003257
after acute coronary syndrome. :@0.544241:0.900561:0.729450:0.900561:0.729450:0.888286:0.544241:0.888286:0.008032:0.003692:0.003986:0.007644:0.003540:0.003257:0.008032:0.007608:0.007150:0.003986:0.007644:0.003257:0.007608:0.007702:0.003540:0.007702:0.007173:0.008032:0.003540:0.006303:0.003257:0.004563:0.006303:0.007173:0.008055:0.003540:0.007702:0.011030:0.007644:0.003257:0.003257
N Engl J Med.:@0.729426:0.900561:0.807073:0.900561:0.807073:0.888286:0.729426:0.888286:0.008702:0.003257:0.006303:0.007173:0.007914:0.002352:0.003257:0.005668:0.003257:0.010807:0.007644:0.008055:0.003257
 2018;379:2097-2107.:@0.807061:0.900561:0.921713:0.900561:0.921713:0.888286:0.807061:0.888286:0.003257:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515:0.003257
17.  sabatine Ms, :@0.519053:0.911597:0.622429:0.911597:0.622429:0.899322:0.519053:0.899322:0.006515:0.006515:0.003257:0.003257:0.005656:0.005856:0.008032:0.008020:0.008032:0.003986:0.002352:0.007173:0.007644:0.003904:0.010807:0.005856:0.003257:0.003257
et al:@0.623076:0.911597:0.648981:0.911597:0.648981:0.899322:0.623076:0.899322:0.007644:0.003986:0.003892:0.008032:0.002352
. Evolocumab and clinical outcomes in patients :@0.648981:0.911597:0.927076:0.911597:0.927076:0.899322:0.648981:0.899322:0.003257:0.003904:0.006303:0.006515:0.007702:0.002352:0.007702:0.007608:0.007150:0.011030:0.008032:0.008020:0.003904:0.008032:0.007173:0.008055:0.003904:0.007608:0.002352:0.002352:0.007173:0.002352:0.007608:0.008032:0.002352:0.003904:0.007702:0.007150:0.003986:0.007608:0.007702:0.011030:0.007644:0.004563:0.003892:0.002352:0.007173:0.003904:0.008020:0.008032:0.003986:0.002352:0.007644:0.007173:0.003986:0.004563:0.003257
with cardiovascular disease. :@0.544253:0.922633:0.708495:0.922633:0.708495:0.910358:0.544253:0.910358:0.009772:0.002352:0.003986:0.007173:0.003257:0.007608:0.008032:0.003540:0.008055:0.002352:0.007702:0.006515:0.008032:0.004563:0.007608:0.007150:0.002352:0.008032:0.003540:0.003257:0.008055:0.002352:0.004563:0.007644:0.008032:0.004563:0.007644:0.003257:0.003257
N Engl J Med. :@0.708495:0.922633:0.789398:0.922633:0.789398:0.910358:0.708495:0.910358:0.008702:0.003257:0.006303:0.007173:0.007914:0.002352:0.003257:0.005668:0.003257:0.010807:0.007644:0.008055:0.003257:0.003257
2017;376:1713-1722.:@0.789387:0.922633:0.900782:0.922633:0.900782:0.910358:0.789387:0.910358:0.006515:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.003257:0.006515:0.006515:0.006515:0.006515:0.003904:0.006515:0.006515:0.006515:0.006515:0.003257
18.  sA dyslipidaemia  guideline consensus statement. :@0.519053:0.933670:0.851029:0.933670:0.851029:0.921394:0.519053:0.921394:0.006515:0.006515:0.003257:0.003257:0.005656:0.005856:0.008702:0.009431:0.008055:0.006303:0.004563:0.002352:0.002352:0.008032:0.002352:0.008055:0.008032:0.007644:0.011030:0.002352:0.008032:0.003257:0.006185:0.007914:0.007150:0.002352:0.008055:0.007644:0.002352:0.002352:0.007173:0.007644:0.009431:0.007608:0.007702:0.007173:0.004563:0.007644:0.007173:0.004563:0.007150:0.004563:0.009431:0.004563:0.003986:0.008032:0.003986:0.007644:0.011030:0.007644:0.007173:0.003986:0.003257:0.003257
SAMJ:@0.857190:0.933670:0.888223:0.933670:0.888223:0.921394:0.857190:0.921394:0.005856:0.008702:0.010807:0.005668
 Nov. :@0.888223:0.933670:0.927087:0.933670:0.927087:0.921394:0.888223:0.921394:0.009431:0.008702:0.007702:0.006515:0.003257:0.003257
2018 ;108 (11) part 2.:@0.544253:0.944706:0.661199:0.944706:0.661199:0.932430:0.544253:0.932430:0.006515:0.006515:0.006515:0.006515:0.003257:0.003257:0.006515:0.006515:0.006515:0.003257:0.004339:0.006515:0.006515:0.004339:0.003257:0.008020:0.008032:0.003540:0.003986:0.003257:0.006515:0.003257